Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (146)	2/13/1999 3:32:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

Peter: A 30% premium for well-capitalized companies, correct? Not for a third-tier, I presume. Hey, I think that I've mentioned GLIA as a munch previously. As I've been expecting, they joined the ranks of profitable biotechs with their release Thursday. Recent developments include the initiation of pivotal trials for Adcon-P and the completion of the single-dose portion of the phase I for GT-2331 (not partnered, and see the new work posted to the TTP thread). The company is firing on all cylinders. Oesterling is doing a masterful job. Further, JNJ (Janssen, munch, munch) is the partner for Alzheimer's (inflammation). Because they turned profitable, the shares shown in Thursday's release include most options..... I think that total potential dilution is only about 600K beyond that shown. Very clean. The GT-2331 phase I showed single dosing for 24 hours. Company estimates number of surgeries for Adcon-P at 3X those for Adcon-L......... exchange2000.com Rick